Compare American States Water Company (AWR) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American States Water Company vs Recursion Pharmaceuticals Inc — how do they compare? American States Water Company trades at $87.83 (market cap $3.47B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: American States Water Company is the larger of the two by market cap, and American States Water Company pays a 2.49% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AWR | RXRX | |
|---|---|---|
Market Cap | $3.47B | $1.81B |
Sector | Utilities | Health |
52-Week High | $89.28 | $6.79 |
52-Week Low | $70.10 | $2.84 |
Enterprise Value | $4.37B | $1.33B |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
American States Water (AWR) trades at $87.45, up 1.02% with a bullish technical outlook. The company reported strong Q2 2026 earnings of $1.09 per share, beating estimates, driven by water rate increases and revenue growth of 11.2%. Profitability remains robust with a 20.52% net income margin and ROE of 13.62%. Recent news highlights AWR's 71-year dividend growth streak and inclusion in TIME's America's Best Companies 2026 list.
AWR offers stable income with consistent dividend growth but faces valuation concerns at 23.92 P/E. Analyst consensus is cautious with 50% hold ratings. Key risks include regulatory dependence and competitive pressures. The stock presents a defensive play with reliable dividends but limited near-term upside given current multiples.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American States Water Company
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
